{"meshTagsMajor":["Mutation"],"meshTags":["Melanoma","Proto-Oncogene Proteins B-raf","Antineoplastic Combined Chemotherapy Protocols","Humans","Treatment Outcome","Protein Kinase Inhibitors","Mutation"],"meshMinor":["Melanoma","Proto-Oncogene Proteins B-raf","Antineoplastic Combined Chemotherapy Protocols","Humans","Treatment Outcome","Protein Kinase Inhibitors"],"genes":["BRAF","MEK","BRAF V600E"],"publicationTypes":["News"],"abstract":"Studies presented or published during the European Society for Medical Oncology conference demonstrate that combining BRAF and MEK inhibitors improves progression-free and overall survival--and lowers the risk of resistance and toxicities--in patients with metastatic melanoma with BRAF V600E or V600K mutations.","title":"Drug combos validated in BRAF-mutant melanoma.","pubmedId":"25477091"}